September 2007
Worldwide Biotech;Sep2007, Vol. 19 Issue 9, p3
Trade Publication
The article reports on the result of a clinical trial on topical microbicide Vivagel conducted by Starpharma Holdings Ltd. The results revealed that Vivagel is well-tolerated and safe in men. In addition, it is suitable for further development as a topical microbicide for the prevention of HIV and genital herpes. The double blinded clinical trial compared the effect of Vivagel on circumcised and uncircumcised men. Vivagel is currently under investigation in female volunteers in separate clinical trials.


Related Articles

  • NIH FUNDS CLINICAL DEVELOPMENT OF VIVAGEL FOR GENITAL HERPES.  // Worldwide Biotech;Jun2006, Vol. 18 Issue 6, p1 

    Reports on the funding agreement established between Starpharma Holdings Ltd. of Melbourne, Victoria and the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Plan by NIAID to fund a clinical trial to test the use of VivaGelâ„¢ in the prevention of genital herpes;...

  • Resiquimod gel cuts recurrence of genital herpes. Guttman, Cheryl // Dermatology Times;Apr2001, Vol. 22 Issue 4, p1 

    Reports the efficacy of resiquimod gel in delaying and decreasing recurrences of genital herpes in immunocompetent patients in the United States. Variation in the effectiveness of delaying recurrences; Use of the gel in treating asymptomatic viral shedding; Manufacturers of resiquimod.

  • Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Strand, A.; Patel, R.; Wulf, H.C.; Coates, K.M.; International Valaciclovir HSV Study Group // Sexually Transmitted Infections;Dec2002, Vol. 78 Issue 6, p435 

    Objectives: In prospective trials, episodic valaciclovir significantly increased the chance of preventing or aborting the development of painful vesicular genital herpes simplex virus (HSV) lesions compared with placebo. We explored the clinical outcome of aborted lesions and its...

  • HIV microbicide trials halted. Wakabi, Wairagala // CMAJ: Canadian Medical Association Journal;5/22/2007, Vol. 176 Issue 11, p1569 

    The article reports on the investigation for ethical breaches during a Phase III clinical trial of Ushercell, an anti-AIDS gel made by Polydex Pharmaceuticals Ltd. in South Africa. The preliminary results of the trial indicate that the use of cellulose sulfate could lead to increased risk of HIV...

  • Next trial for Starpharma.  // Australian Life Scientist;8/13/2008, p1 

    Starpharma studies VivaGel duration

  • Biotech ADRs With Near-Term Commercialization Potential. HADDAD, ANTHONY W. // Equities;Oct2009, Vol. 58 Issue 4, p52 

    The article offers information on biotech companies with potential for commercialization whose share prices have doubled for the past 12 months. Starpharma Holdings' lead product VivaGel showed good results in clinical trials and uses nanotechology in preventing the transmission of sexually...

  • Of microbiocides, women and men. Burkitt, Vicki // HIV Australia;Dec2003-Feb2004, Vol. 3 Issue 2, p26 

    Provides information on several clinical trials that tested the effectiveness of microbicides in preventing HIV transmission. Results of a study on the microbicide Nonoxynol-9 (N-9) tested in female sex workers; Damage done by N-9 to the subjects; Number of microbicides allocated for clinical...

  • Genital herpes vaccine shows limited promise. Stephenson, Joan; Stephenson, J // JAMA: Journal of the American Medical Association;10/18/2000, Vol. 284 Issue 15, p1913 

    States that a vaccine against genital herpes infections appears to protect people against the disease, but has limitations that may have implications for vaccines against sexually transmitted diseases (STD). Report unveiled at the 40th Interscience Conference on Antimicrobial Agents and...

  • Antiviral treatment of genital herpes. Apoola, A.; Radcliffe, K. // International Journal of STD & AIDS;Jul2004, Vol. 15 Issue 7, p429 

    A review of the randomized, controlled trials in the literature on the treatment of genital herpes infection with aciclovir, famciclovir and valaciclovir. Common clinical questions encountered by physicians, such as the effect of antivirals on symptoms, healing, aborting attacks and subsequent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics